Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209597 · ClinicalTrials.gov registry record · Phase 4
Clinical Study of Generic and Brand Bupropion in Depression
A Phase 4 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 74
- Enrollment target
NCT02209597 is a Phase 4 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 74 participants.
The verdict
NCT02209597, a Phase 4 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 74 participants
- Enrollment target
Study Summary
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
Interventions
- DRUG Bupropion XL 300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2016-08-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209597
The ClinicalTrials.gov registry entry for NCT02209597 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion XL 300 is the first listed.
NCT02209597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209597 about?
NCT02209597 is a clinical study titled "Clinical Study of Generic and Brand Bupropion in Depression". Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
What is the current status of trial NCT02209597?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2014-06-25. Estimated completion is 2016-08-14.
What interventions are being tested in trial NCT02209597?
The interventions under investigation include: Bupropion XL 300 (DRUG).
Who is sponsoring clinical trial NCT02209597?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.